Malaysia
Search
Sign In
Rheumatology
Top Medical News
In the treatment of patients with rheumatoid arthritis (RA) and atherosclerotic cardiovascular disease (ASCVD), the use of tofacitinib confers an increased risk of major adverse cardiovascular events (MACE) than tumour necrosis factor inhibitors (TNFi), according to a post hoc analysis of ORAL Surveillance.
In the phase II TRAIL1 trial, oral pirfenidone slowed the rate of decline in lung function in individuals with rheumatoid arthritis-associated interstitial lung disease (RA-ILD).
Despite being vaccinated against COVID-19, women with gout have an excess risk of developing SARS-CoV-2 infection as well as severe sequelae from it, according to a study.
Adalimumab soln for inj 40 mg/0.8 mL
Symptomatic adverse events (AEs) are common and troublesome for many patients with rheumatoid arthritis (RA) who are taking medications for their condition, results of an exploratory study have shown.
Patients who undergo sural nerve biopsy (SNB) have a better diagnostic yield for vasculitis, results of a study have shown.
The presence of dactylitis in patients with axial psoriatic arthritis (axPsA) may result in higher disease activity and more severe joint damage compared to those without, reports a study.
Special Reports
Adalimumab soln for inj 40 mg/0.8 mL
Esflurbiprofen 40 mg transdermal patch
Upadacitinib 15 mg XR-FC tab
Romosozumab 105 mg/1.17 mL soln for inj
Conference Reports
In patients with juvenile idiopathic arthritis (JIA) with insufficient response to conventional synthetic (cs) or biologic (b) disease-modifying antirheumatic drugs (DMARDs), the JAK*1/2 selective inhibitor baricitinib reduced the frequency and delayed time to disease flares, according to a phase III trial presented at EULAR 2022.
Patients with psoriatic arthritis (PsA) with no prior exposure to biological disease-modifying antirheumatic drugs (bDMARDs) experience improvements in their condition when treated with bimekizumab, according to results of the phase III BE OPTIMAL trial.
Treatment with bimekizumab, a monoclonal IgG1 antibody that selectively inhibits interleukin (IL)-17F and IL-17A, significantly improved ASAS40* response rate in patients with either nonradiographic axial spondyloarthritis (nr-axSpA) or ankylosing spondylitis (AS**), according to two phase III studies presented at EULAR 2022.
The use of antihistamines was associated with reduced structural progression in knee osteoarthritis (OA), according to a post hoc analysis of two large phase III trials.
Treatment with upadacitinib improves disease activity, pain, function, and quality of life (QoL) in patients with non-radiographic axial spondyloarthritis (nr-axSpA) in a study touted as the first to evaluate a Janus kinase (JAK) inhibitor for this condition.
The monoclonal antibody sarilumab demonstrated significant efficacy in individuals with relapsing polymyalgia rheumatica (PMR), findings from the phase III SAPHYR trial have shown.
In the postintervention results of the VITAL* trial, vitamin D and marine omega-3 fatty acids (n-3 FAs) continued to demonstrate a protective effect against autoimmune diseases in older adults.
